Clinical treatment trials are studies that try to improve prevention, advance current treatment or find new treatments for diseases. They are the only reliable way to prove the effectiveness of various treatments. During a clinical trial, information is carefully collected to assess improvement in outcomes, and risks that may be associated with new treatments.
Please keep in mind that there are many different types of diseases, and the medical names can sound confusingly similar, especially for closely related diseases and for different stages of the same disease. You should discuss your diagnosis with your physician and know what your situation is before drawing any conclusions or making any decisions.
For more information, please call (803) 434-3680 or 1-800-775-2287.
| |
Clinical Treatment Trials with Palmetto Health Institutional Review Board approval. |
| Disease: Acute Lymphoblastic Leukemia |
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2004-41
|
COG
|
AALL0232
|
High Risk B-precursor Acute Lymphoblastic Leukemia.
|
Linda Sherriff
(803) 434-3907
|
|
2004-42
|
COG
|
AALL03B1
|
Classification of Acute Lymphoblastic Leukemia.
|
Linda Sherriff
(803) 434-3907
|
|
2007-82
|
COG
|
AALL0433
|
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies, A Groupwide Phase III Study.
|
Linda Sherriff, RN
(803) 434-3907
|
|
2007-76
|
COG
|
AALL0434
|
Intensified Methotrexate, Nelarabine (Compound 506U78; IND # 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia: A Groupwide Phase III Study.
|
Linda Sherriff
(803) 434-3907
|
|
2007-09
|
COG
|
AALL05B1
|
A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens.
|
Linda Sherriff
(803) 434-3907
|
|
2005-31
|
COG
|
AALL0331
|
Standard Risk B-precursor Acute Lymphoblastic Leukemia.
|
Linda Sherriff
(803) 434-4795
|
| Disease: Acute Myeloid Leukemia |
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2007-17
|
COG
|
AAML0531
|
A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults.
|
Linda Sherriff
(803) 434-3907
|
| Disease: Adenomatous Colorectal Polyps (ACP) |
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2008-77
|
SWOG
|
S0000D
|
A Study of the Effect of Vitamin E and/or Selenium on Adenomatous Colorectal Polyps (ACP) in Participants Enrolled in SELECT, Phase III Ancillary to S0000-SELECT
|
Linda Sherriff
(803) 434-3907
|
| Disease: Alzheimer's Disease |
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2004-39
|
South Carolina Alzheimer's Disease Research Center/MUSC
|
|
South Carolina Alzheimer's Disease Research Center Clinical Core Study (ADRC-CCS).
|
Linda Sherriff
(803) 434-3907
|
|
2007-88
|
SWOG
|
S0000A
|
Prevention of Alzheimer's Disease with Vitamin E and Selenium Trial (PREADVISE), Phase III Ancillary to S0000 - SELECT.
|
Linda Sherriff
(803) 434-3907
|
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2009-76
|
GSK
|
|
A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared with Placebo in Subjects with Chronic Obstructive
|
Adreane Burgess, RN
(803) 434-3907
|
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2002-81
|
Department of Housing and Urban Development
|
|
JOMED JOSTENT Coronary Stent Graft-Humanitarian Use Device.
|
Benjamin R. Jones, M.D.
(803) 434-3907
|
|
2010-10
|
Boston Scientific
|
|
TAXUS® Liberté® Paclitaxel-Eluting Coronary Stent System U.S. Post-Approval Study
|
Adreane Burgess, RN
(803) 434-3907
|
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2007-115
|
|
|
Exploring effectiveness of dynamic balance training program intervention- “Stay in Balance”- to improve fall risk in community dwelling Older adults.
|
Margaret M. Matthews, M.D., Ph.D.
Michele Neese, RN
(803) 434-3907
|
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
97-32
|
CDC
|
1671
|
Universal Data and Serum Specimen Collection System for Hemophilia
|
Linda Sherriff
(803) 434-3907
|
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2008-101
|
Merck & Company, Inc.
|
MK-0518-055
|
A Study to Evaluate the Safety, Tolerability, and Efficacy of MK-0518/Raltegravir in HIV-Infected Patients.
|
Helmut Albrecht, MD
Nancy Haase, RN
(803) 434-3907
|
|
2007-117
|
Tibotec Pharmaceuticals
|
|
A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a fixed background regimen consisting of tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive HIV-1 infected subjects
|
Helmut Albrecht, MD
Nancy Haase, RN
(803) 434-3907
|
|
2010-30
|
Gilead Sciences/PPD, Inc.
|
|
GS-US-236-0102: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected,
|
Nancy Haase, RN
(803) 434-3907
|
|
2010-31
|
Gilead Sciences/PPD, Inc.
|
|
GS-US-236-0103: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/ Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected,
|
Helmut Albrecht, MD
Nancy Haase, RN
(803) 434-3907
|
|
2010-48
|
Gilead Sciences/PPD, Inc.
|
|
Gilead GS-US-216-0114: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral
|
Helmut Albrecht, MD
Nancy Haase, RN
(803) 434-3907
|
| Disease: Hodgkin's Disease |
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2006-27
|
COG
|
AHOD03P1
|
Treatment of Children with Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkins Disease (LPHD).
|
Linda Sherriff
(803) 434-3907
|
|
2007-10
|
COG
|
AHOD04B1
|
Banking in Hodgkin Disease.
|
Linda Sherriff
(803) 434-3907
|
|
2007-107
|
COG
|
AHOD0521
|
A Phase II Study of Bortezomib (Velcade, PS-341, IND # 58443) in Combination with Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults with Refractory/Recurrent Hodgkin Disease.
|
Linda Sherriff
(803) 434-3907
|
| Disease: Inflammatory Bowel Disease |
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2009-18
|
Crohn's and Colitis Foundation of America
|
|
The Role of Adipokines in Inflammatory Bowel Disease.
|
Raja Fayad, M.D.
(803) 777-2918
|
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2007-07
|
|
04-MCH-343-ORC
|
A Study of Decisions Surrounding Lung Cancer Surgery.
|
Linda Sherriff
(803) 434-3907
|
| Disease: Methotrexate Toxicity |
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2009-49
|
Protherics
|
Pr001-CLN-pro016
|
An Open-Label Treatment Protocol for the Use of Voraxaze as Adjunctive Treatment for Patients Experiencing or at Risk of Methotrexate Toxicity.
|
Linda Sherriff
(803) 434-3907
|
| Disease: Nasopharyngeal Carcinoma |
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2006-92
|
COG
|
ARAR0331
|
Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy.
|
Linda Sherriff
(803) 434-3907
|
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2001-63
|
COG
|
ANBL00B1
|
Neuroblastoma Biology Studies.
|
Linda Sherriff
(803) 434-3907
|
|
2002-92
|
COG
|
ANBL00P2
|
Perinatal Neuroblastoma: Expectant Observation. A COG Pilot Study.
|
Linda Sherriff
(803) 434-3907
|
|
2002-96
|
COG
|
ANBL0032
|
Phase III Randomized Study of Chimeric Antibody 14.18 in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue.
|
Linda Sherriff
(803) 434-3907
|
|
2008-26
|
COG
|
|
Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma, A Groupwide Phase III Study
|
Linda Sherriff
(803) 434-3907
|
|
2008-115
|
COG
|
ANBL0532
|
Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma.
|
Linda Sherriff
(803) 434-3907
|
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2010-25
|
NIH
|
|
APCAST: Activated Protein C in Acute Stroke Trial
|
Souvik Sen, MD
Shelley Laird, LPN
(803) 434-3907
|
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2005-58
|
|
|
Saline Infusion Sonography to Determine Bilateral Tubal Occlusion in Women After Hysteroscopic Bilateral Tubaligation by Essure Microinserts.
|
Stanette Brown
(803) 779-4928
|
|
2006-119
|
American Medical Systems, Inc.
|
|
Clinical Study Protocol Number 1004: A Prospective, Multi-Center Study to Assess the AMS Pelvic Floor Repair System Devices for Prolapse Repair.
|
Stanette Brown
(803) 779-4928
|
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2007-145
|
Stryker Biotech
|
|
OP-1 Implant (HUD).
|
Dr. Michael Tucker
Orthopedics
(803) 434-3907
|
|
2009-65
|
Small Bone Innovations, Inc.
|
|
Use of Small Bone Innovations Metacarpophalangeal (MCP) finger prosthesis. Humanitarian Use Device.
|
Michael Green, M.D.
(803) 434-3907
|
|
2009-66
|
Small Bone Innovations, Inc.
|
|
Use of Small Bone Innovations Proximal Interphalangeal (PIP) finger prosthesis. Humanitarian Use Device.
|
Michael Green, M.D.
|
|
2009-040
|
Amgen, Inc.
|
|
A Multi-center, Randomized, Double blind, Placebo-controlled Study of AMG 785 in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture Status Post Definitive Fracture Fixation with an Intramedullary Nail
|
Michael Tucker, MD
Shelley Laird, LPN
(803) 434-3907
|
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2005-89
|
COG
|
AOST0331
|
A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma based on Histological Response to Pre-Operative Chemotherapy, A Phase III Intergroup Study.
|
Linda Sherriff
(803) 434-3907
|
|
2008-126
|
COG
|
AOST06B1
|
A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens.
|
Linda Sherriff
(803) 434-3907
|
|
2008-143
|
COG
|
AOST06P1
|
Feasibility and Dose Discovery Analysis of Zoledronic Acid with Concurrent Chemotherapy in the Treatment of Newly Diagnosed Metastatic Osteosarcoma, A Groupwide Pilot Study.
|
Linda Sherriff, RN
(803) 434-3907
|
| Disease: Ovarian Stromal Tumors |
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2001-07
|
GOG
|
187
|
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as First-Line Therapy or Second-Line Therapy
|
Dr. James Williams
(803) 434-3907
|
| Disease: Pediatric Acute Lymphoblastic Leukemia |
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2005-31
|
COG
|
AALL0331
|
Standard Risk B-precursor Acute Lymphoblastic Leukemia.
|
Linda Sherriff, RN
(803) 434-3907
|
|
2005-46
|
COG
|
AALL03N1
|
Understanding the Role of Adherence in the Ethnic Differences in Survival after Childhood ALL.
|
Linda Sherriff
(803) 434-3907
|
| Disease: Pediatric Brain Tumors |
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2005-10
|
COG
|
ACNS02B3
|
Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens.
|
Linda Sherriff
(803) 434-3907
|
|
2006-23
|
COG
|
ACNS0221
|
A Phase II Study of Conformal Radiotherapy in Patients with Low-Grade Gliomas.
|
Linda Sherriff
(803) 434-3907
|
|
2007-81
|
COG
|
ACNS0332
|
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients.
|
Linda Sherriff
(803) 434-3907
|
|
2005-21
|
COG
|
AGCT0132
|
A Phase III Study of Reduced Therapy in the Treatment of Children with Low and Intermediate Risk Extracranial Germ Cell Tumors.
|
Linda Sherriff
(803) 434-3907
|
| Disease: Pediatric Hemophilia |
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2010-04
|
NIH
|
|
Go Grant: Mechanisms of Race-Based Differences in Factor VIII Immunogenicity in Hemophilia
|
Janice Withycombe, RN
(803) 434-3907
|
| Disease: Pediatric Low-Risk Rhabdomyosarcoma |
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2005-45
|
COG
|
ARST0331
|
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide with or without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma.
|
Linda Sherriff, RN
(803) 434-3907
|
|
2007-15
|
COG
|
ARST0531
|
Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS).
|
Linda Sherriff
(803) 434-3907
|
| Disease: Pediatric Oncology |
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2010-13
|
Merck & Co.
|
|
Merck 0869-134: A Multi-center, Open-label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy
|
Janice Withycombe, RN
(803) 434-3907
|
| Disease: Pediatric Rhabdomyosarcoma |
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2008-36
|
COG
|
ADVL0221
|
A Phase II Study of Trabectedin (ET-743, Yondelis) in Children with Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Nonrhabdomyosarcomatous Soft Tissue Sarcomas.
|
Linda Sherriff, RN
(803) 434-3907
|
| Disease: Pediatric Solid Tumors |
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2009-25
|
Children's Oncology Group
|
ADVL0821
|
A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, IND #100947, NSC #742460) in Children With Relapsed/Refractory Solid Tumors.
|
Linda Sherriff, RN
(803) 434-3907
|
| Disease: Pediatric Standard Risk Medulloblastoma |
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2004-44
|
COG
|
ACNS0331
|
A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial.
|
Linda Sherriff, RN
(803) 434-3907
|
| Disease: Pediatric Wilms Tumor |
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
96-51
|
COG
|
4941L
|
National Wilms Tumor Late Effects Study
|
Linda Sherriff, RN
(803) 434-3907
|
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2008-12
|
National Institutes of Mental Health/NIH/DHHS
|
|
Cohort Study of Religiosity, Social Support, and Postpartum Depression and Anxiety.
|
Allyson Palmer
(803) 434-3907
|
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2007-19
|
|
|
Maternal and Newborn Outcomes of Patients Attending the Management of Obesity in Pregnancy Clinic: Data Collection and Analysis for Patient Quality Improvement and Publication.
|
Stanette Brown, R.N.
(803) 779-4928, ext 252
|
|
2008-33
|
|
|
Pilot Study: The Impact of Sleep Apnea on Pregnancy and the Health of Women and Neonates.
|
Stanette Brown
(803)779-4928
|
|
2006-103
|
Environmental Protection Agency
|
|
Pregnancy, Environment and Child Health Study (PEACH).
|
Stanette Brown
(803) 779-4928
|
|
2009-67
|
USC School of Medicine
|
|
Vaginal Infection and Inflammation in Maternal Serum, Amniotic Fluid and Umbilical Cord Blood.
|
Stanette Brown
(803) 779-4928
|
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2004-62
|
National Cancer Institute/NIH/DHHS
|
|
Teleconference Group: Breast Cancer In African-Americans.
|
Sue Heiney, Ph.D.
(803) 434-3907
|
| Disease: Recurrent Malignanices |
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2007-151
|
COG
|
ADVL0525
|
A Phase II Study of Pemetrexed in Children with Recurrent Malignancies, A COG Group Wide Phase II Study.
|
Linda Sherriff, RN
(803) 434-3907
|
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2008-03
|
COG
|
ACCRN07
|
Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network(CCRN).
|
Linda Sherriff, RN
(803) 434-3907
|
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2007-13
|
COG
|
AREN0532
|
Low and Standard Risk Renal Tumors.
|
Linda Sherriff, RN
(803) 434-3907
|
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2007-12
|
COG
|
AREN0321
|
Treatment of High Risk Renal Tumors.
|
Linda Sherriff, RN
(803) 434-3907
|
|
2006-56
|
COG
|
AREN03B2
|
Renal Tumors Classification, Biology, and Banking Study.
|
Linda Sherriff, RN
(803) 434-3907
|
|
2007-104
|
COG
|
AREN0533
|
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors.
|
Linda Sherriff, RN
(803) 434-3907
|
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2006-73
|
Eisai Global Clinical Development
|
E5564-G000-301
|
ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis.
|
Linda Sherriff, RN
(803) 434-3907
|
|
2008-19
|
Artisan Pharma, Inc.
|
2-001
|
A Randomized, Double-blind, Placebo-Controlled, Phase-2b Study to Assess The Safety and Efficacy Effects of ART-123 on Subjects with Sepsis and Disseminated Intravascular Coagulation.
|
Linda Sherriff, RN
(803) 434-3907
|
| Disease: Severe Chronic Neutropenia Registry |
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
95-83
|
SCNIR
|
|
Severe Chronic Neutropenia International Registry
|
Linda Sherriff, RN
(803) 434-3907
|
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2007-92
|
Bristol-Myers Squibb Research and Development
|
CV185030
|
A Phase III, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects with Nonvalvular Atrial Fibrillation.
|
Linda Sherriff, RN
(803) 434-3907
|
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2003-59
|
|
|
A Tissue Bank for the South Carolina Cancer Center.
|
Linda Sherriff
(803) 434-3907
|
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2007-108
|
Western Trauma Association Foundation Multi-Center Studies Group/American Association of the Surgery of Trauma
|
|
The Use of rFactor VIIa in Trauma Patients: A Western Trauma Association/American Association of the Surgery of Trauma Multi-Center Case Registry.
|
James Morrison, M.D.
Dept. of Surgery
|
|
2010-37
|
NIH
|
|
PH IRB #2010-37; Pro00006040; Protocol No. 13447: Surgical Infection Society (SIS) Multicenter Study of Duration of Antibiotics for Intraabdominal Infection
|
Christopher Watson, MD
Georgia Welnick, RN
Shelley Laird, LPN
(803) 434-3907
|
| IRB # |
Sponsor |
Study # |
Study Title |
Contact |
|
2009-57
|
Novo Nordisk, Inc.
|
NN1250-3579
|
A 52-Week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-Target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination with Oral Anti-Diabetic Drugs (AD), in Subjects with Type 2 Diabetes Mellitus Currently Treated with OAD(s) and Qualifying from More Intensified Treatment.
|
Tu Lin, M.D.
(803) 434-3907
|
|
